Section Arrow
HOOK.NASDAQ
- HOOKIPA Pharma Inc.
Quotes are at least 15-min delayed:2025/06/04 01:05 EDT
Last
 1.58
+0.01 (+0.64%)
Day High 
1.65 
Prev. Close
1.57 
1-M High
1.7699 
Volume 
91.22K 
Bid
1.51
Ask
1.6
Day Low
1.51 
Open
1.56 
1-M Low
1.1401 
Market Cap 
19.14M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.59 
20-SMA 1.51 
50-SMA 1.17 
52-W High 8.901 
52-W Low 0.721 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.85/-2.14
Enterprise Value
19.46M
Balance Sheet
Book Value Per Share
2.80
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
43.95M
Operating Revenue Per Share
1.31
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed:2025/06/04 01:05 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program,HB-500, are being developed in partnership with Gilead.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.